Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans

Journal of Clinical Microbiology

Volumn 41, Issue 1, 2003, Pages 267-272

  Yamazumi, T ^a   Pfaller, Michael A ^b   Messer, S A ^b   Houston, A K ^b   Boyken, L ^b   Hollis, R J ^b   Furuta, I ^a   Jones, R N ^b  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kinki Univ School of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ARTICLE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; EXPOSURE; FUNGAL STRAIN; FUNGUS ISOLATION; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TEMPERATURE SENSITIVITY;

ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; TEMPERATURE;

FILOBASIDIELLA NEOFORMANS; FUNGI;

EID: 12244299436     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.1.267-272.2003     Document Type: Article

References (30)

1. Armengou, A., C. Porcar, J. Mascaro, and F. Garcia-Bragado. 1996. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 23:1337-1338.
2. Barchiesi, F., R. J. Hollis, S. A. Messer, G. Scalise, M. G. Rinaldi, and M. A. Pfaller. 1995. Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients. Diagn. Microbiol. Infect. Dis. 23:99-103.
3. Barchiesi, F., D. Calabrese, D. Sanglard, L. Falconi Di Francesco, F. Caselli, D. Giannini, A. Giacometti, S. Gavaudan, and G. Scalise. 2000. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob. Agents Chemother. 44:1578-1584.
4. Berg, J., C. J. Clancy, and M. H. Nguyen. 1998. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin. Infect. Dis. 26:186-187.
5. Brandt, M. E., M. A. Pfaller, R. A. Hajjeh, E. A. Graviss, J. Rees, E. D. Spitzer, R. W. Pinner, L. W. Mayer, et al. 1996. Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus associated cryptococcosis. J. Infect. Dis. 174:812-820.
6. Brandt, M. E., M. A. Pfaller, R. A. Hajjeh, R. J. Hamill, P. G. Pappas, A. L. Reingold, D. Rimland, and D. W. Warnock for the Cryptococcal Disease Active Surveillance Group. 2001. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob. Agents Chemother. 45:3065-3069.
7. Calvet, H. M., M. R. Yeaman, and S. G. Filler. 1997. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob. Agents Chemother. 41:535-539.
8. Casadevall, A., and J. R. Perfect (ed.). 1998. Epidemiology, p. 351-380. In Cryptococcus neoformans. American Society for Microbiology, Washington, D.C.
9. Casadevall, A., and J. R. Perfect (ed.). 1998. Therapy of cryptococcosis, p. 457-518. In Cryptococcus neoformans. American Society for Microbiology, Washington, D.C.
10. Chambers, H. F. 1997. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev. 10:781-791.
11. Espinel-Ingroff, A., M. Pfaller, M. E. Erwin, and R. N. Jones. 1996. Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J. Clin. Microbiol. 34:848-852.
12. Hajjeh, R. A., M. E. Brandt, and R. W. Pinner. 1995. Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Epidemiol. Rev. 17:303-320.
13. Kirkpatrick W. R., R. K. McAtee, S. G. Revankar, A. W. Fothergill, D. I. McCarthy, M. G. Rinaldi, and T. F. Patterson. 1998. Comparative evaluation of National Committee for Clinical Laboratory Standards broth macrodilution and agar dilution screening methods for testing fluconazole susceptibility of Cryptococcus neoformans. J. Clin. Microbiol. 36:1330-1332.
14. Marr, K. A., C. N. Lyons, T. R. Rustad, R. A. Bowden, T. C. White, and T. Rustad. 1998. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob. Agents Chemother. 42:2584-2589.
15. Marr, K. A., C. N. Lyons, K. Ha, T. R. Rustad, and T. C. White. 2001. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob. Agents Chemother. 45:52-59.
16. Matthews, P. R., and P. R. Stewart. 1984. Resistance heterogeneity in methicillin-resistant Staphylococcus aureus. FEMS Microbiol. Lett. 11:161-166.
17. Mitchell, T. G., and J. R. Perfect. 1995. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515-548.
18. Mondon, P., R. Petter, G. Amalfitano, R. Luzzati, E. Concia, I. Polacheck, and K. J. Kwon-Chung. 1999. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob. Agents Chemother. 43:1856-1861.
19. Moran, G. P., D. J. Sullivan, M. C. Henman, C. E. McCreary, B. J. Harrington, D. B. Shanley, and D. C. Coleman. 1997. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob. Agents Chemother. 41:617-623.
20. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Pfaller, M. A., J. Zhang, S. Messer, M. Tumberland, E. Mbidde, C. Jessup, and M. Ghannoum. 1998. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients. Diagn. Microb. Infect. Dis. 32:191-199.
22. Pfaller, M. A., J. Zhang, S. A. Messer, M. E. Brandt, R. A. Hajjeh, C. J. Jessup, M. Tumberland, E. K. Mbidde, and M. A. Ghannoum. 1999. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob. Agents Chemother. 43:169-171.
23. Powderly, W. G., D. M. Finkelstein, J. Feinberg, P. T. Frame, W. He, C. M. van der Horst, S. L. Koletar, M. E. Eyster, J. Carey, H. A. Waskin, T. M. Hooton, N. E. Hyslop, S. A. Spector, and S. A. Bozzette. 1995. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 332:700-705.
24. Prugam, A., J. Dupouy-Camet, P. Blanche, J. P. Gangneux, C. TourteSchaefer, and D. Sicard. 1994. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin. Infect. Dis. 19:975-976.
25. Sanati, H., S. A. Messer, M. A. Pfaller, M. Witt, R. Larsen, A. EspinelIngroff, and M. Ghannoum. 1996. Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole. J. Clin. Microbiol. 34:1280-1282.
26. Thornewell, S. J., R. B. Peery, and P. L. Skatrud. 1997. Cloning and characterization of CneMDR1: a Cryptococcus neoformans gene encoding a protein related to multidrug resistance proteins. Gene 201:21-29.
27. Venkateswarlu, K., M. Taylor, N. J. Manning, M. G. Rinaldi, and S. L. Kelly. 1997. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:748-751.
28. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
29. Xu, J., C. Onyewu, H. J. Yoell, R. Y. Ali, R. J. Vilgalys, and T. G. Mitchell. 2001. Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans. Antimicrob. Agents Chemother. 45:420-427.
30. Yamazumi, T., M. A. Pfaller, S. A. Messer, A. Houston, R. J. Hollis, and R. N. Jones. 2000. In vitro activities of ravuconazole (BMS-207147) against clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:2883-2886.